A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
NEW YORK, March 29, 2017 -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the 12 months ended December 31, 2016. Highlights for the fourth...
Company Plans to file 2016 Fourth Quarter and Year End Financial Results by March 30, 2017 NEW YORK, March 27, 2017 -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces...
NEW YORK, March 10, 2017 -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, today announced that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of...
Single-Center Retrospective Data Also Demonstrate Therapy Extends Progression-Free Survival by 9 Months NEW YORK, Feb. 22, 2017 -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers,...
Retrospective Analysis of Outcomes with Investigational Melphalan/HDS and Commercial CHEMOSAT® Projects Median Overall Survival to be 657 Days; 1,207 Days for Responders NEW YORK, Feb. 21, 2017 -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology...
NEW YORK, Jan. 23, 2017 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, today announced that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of...
NEW YORK, Jan. 18, 2017 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, today announced that new data from a retrospective study of Melphalan/HDS, entitled "Percutaneous...
Company Accepts Invitation from Cholangiocarcinoma Foundation to Present Initial Signals in ICCNEW YORK, Jan. 12, 2017 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers,...
NEW YORK, Nov. 11, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces financial results for the three and nine months ended September 30, 2016. Highlights for the...
NEW YORK, Oct. 18, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH) (the "Company"), an interventional oncology company focused on treatments for primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive...